medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (1)

Integral treatment of epileptomas and long term epilepsy associated tumors

Font-Réaulx RE, Terrazo LJ, Shkurovich BP, Collado CMÁ, Ramírez NE, González AA

Language: Spanish
References: 24
Page: 29-33
PDF size: 247.75 Kb.


ABSTRACT

Virtually any intra or extra axial neoplasm can cause epilepsy in humans, regardless of its histological lineage. The term epileptoma is used conceptually to define those tumors that require a broader neurosurgical strategy, which encompasses an oncological approach in conjunction with specialized epilepsy surgery techniques, to ideally obtain a complete tumor resection and long-term seizures freedom for the patient, emphasizing a survival without epilepsy and not just tumor control. There are several histological types and locations of epileptomas and a known highly epileptogenic subgroup are the long-term epilepsy associated tumors. Depending on each particular case, it should be decided which preoperative studies should be performed, considering in some cases advanced neurophysiological techniques such as the placement of electrodes by stereoelectroencephalography and/or subdural electrodes to perform a long-term monitoring that yields enough data to make the most appropriate neuro-oncological and epilepsy surgery planning.


REFERENCES

  1. Blumcke I, Aronika E, Urbach H, Alexopoulos A, González-Martínez JA. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol. 2014; 128 (1): 39-54.

  2. Blumcke I, Wiestler OD. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol. 2002; 61 (7): 575-584.

  3. Japp A, Gielen GH, Becker AJ. Recent aspects of classification and epidemiology of epilepsy-associated tumors. Epilepsia. 2013; 54 (Suppl 9): 5-11.

  4. Piao YS, Lu DH, Chen L, Liu J, Wang W, Liu L et al. Neuropathological findings in intractable epilepsy: 435 Chinese cases. Brain Pathol. 2010; 20 (5): 902-908.

  5. Prayson RA. Brain tumors in adults with medically intractable epilepsy. Am J Clin Pathol. 2011; 136 (4): 557-563. doi: 10.1309/AJCP0RBUQAQPZOUe.

  6. Thom M, Blumcke I, Aronica E. Long-term epilepsy-associated tumors. Brain Pathol. 2012; 22 (3): 350-379.

  7. Wolf HK, Wiestler OD. Surgical pathology of chronic epileptic seizure disorders. Brain Pathol. 1993; 3 (4): 371-380.

  8. Duncan JS, de Tisi J. MRI in the diagnosis and management of epileptomas. Epilepsia. 2013; 54 (Suppl 9): 40-43.

  9. Hamer HM, Hong SB. Is an epilepsy presurgical evaluation necessary for mid-grade and high-grade brain tumors presenting with seizures? Epilepsia. 2013; 54 (Suppl 9): 56-60.

  10. Kennedy J, Schuele SU. Long-term monitoring of brain tumors: when is it necessary? Epilepsia. 2013; 54 (Suppl 9): 50-55.

  11. Rosenow F, Menzler K. Invasive EEG studies in tumor related epilepsy: when are they indicated and with what kind of electrodes? Epilepsia. 2013; 54 (Suppl 9): 61-65.

  12. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A et al. The clinicopathological spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia. 2011; 52 (1): 158-174.

  13. Palmini A, Paglioli E, Silva vD. Developmental tumors and adjacent cortical dysplasia: single or dual pathology? Epilepsia. 2013; 54 (Suppl 9): 18-24.

  14. Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A et al. Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol. 2001; 27 (2): 105-114.

  15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116 (6): 597-602.

  16. Ostrom Q, Cohen ML, Ondracek A, Sloan A, Barnholtz-Sloan J. Gene markers in brain tumors: what the epileptologist should know. Epilepsia. 2013; 54 Suppl 9 (0-9): 25-29.

  17. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321 (5897): 1807-1812.

  18. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360 (8): 765-773.

  19. Blumcke I, Giencke K, wardelmann E, Beyenburg S, Kral T, Sarioglu N et al. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol. 1999; 97 (5): 481-490.

  20. Lhatoo SD, Moghimi N, Schuele S. Tumor-related epilepsy and epilepsy surgery. Epilepsia. 2013; 54 (Suppl 9): 1-4.

  21. Rogers LR. Chemotherapy and immunotherapy of brain tumors: what the epileptologist must know. Epilepsia. 2013; 54 (Suppl 9): 105-108.

  22. Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013; 54 (Suppl 9): 97-104.

  23. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001; 345 (5): 311-318.

  24. Becker AJ, Blumcke I, Urbach H, Hans V, Majores M. Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol. 2006; 65 (2): 99-108.



EVIDENCE LEVEL

III




2020     |     www.medigraphic.com